- Trial phase
- Approved
- Time to market
- Already on the market. The FDA approved SimpleScreen CRC on July 27, 2026. Abbott commercially launched the test in the United States in late September 2026.
- Why 4/10
- SimpleScreen CRC is already FDA-approved and commercially launched with no upcoming PDUFA or pivotal-readout catalyst in the next ~12 months. The next potential regulatory catalyst would be an FDA submission for the next-generation version, for which no filing date has been announced. As an approved, marketed product, the defining binary has passed, capping the impact score at 5, and the lack of a near-term dated catalyst holds it at 4.
SimpleScreen CRC's defining binary (FDA approval) has passed, removing the high-impact binary catalyst. The stock now trades on the commercial execution story via Abbott and on pipeline expansion (lung test). Watch Q4 2026 revenue (due early 2027) for evidence of recurring test-sale volume versus one-time milestones; the next-gen validation data and a potential FDA filing for the updated version are the next potential catalysts to watch for.
Price Chart
Executive Summary
Freenome's SimpleScreen CRC is a blood-based colorectal cancer screening test that won FDA approval in July 2026 and was commercially launched in the US by partner Abbott in late September 2026. Q32026 revenue of $183.5 million (versus $1 million a year earlier) was driven largely by milestone payments from Abbott, and the company beat EPS estimates ($0.57 actual vs $0.41 consensus). The test competes with Guardant Health's Shield blood test (approved 2024) and stool-based tests (Cologuard Plus, now also owned by Abbott). The stock trades at $10.41, well below the $18 mean analyst target, though the approved status and partnership with Abbott provide a commercial floor while a next-gen version and newly launched SimpleScreen Lung represent pipeline upside.
How It Works
SimpleScreen CRC is a blood test that screens for colorectal cancer by detecting multiple biological signals (DNA, RNA, proteins) shed by tumors into the bloodstream. A doctor draws blood in the office; results come back in about two weeks. A positive result requires a follow-up colonoscopy.
Trial Status
SimpleScreen CRC completed a pivotal clinical validation study whose top-line readout on July 9, 2026 showed it met all primary and secondary endpoints. The test achieved approximately 81% sensitivity for colorectal cancer detection in average-risk adults 45+. An updated version of the test presented at the American College of Gastroenterology (ACG) meeting in October 2026 showed improved detection of advanced precancerous lesions (18.2% sensitivity, up from the original version).
The Two-Sided Case
Upcoming Catalysts
- Commercial ramp and recurring test-volume revenue updates from Freenome (next quarterly earnings)
- Potential FDA submission timing for the next-generation version of SimpleScreen CRC with improved precancerous-lesion detection
- SimpleScreen Lung Breakthrough Device designation progress and potential FDA approval pathway
- Insurance coverage decisions and Medicare reimbursement updates for SimpleScreen CRC
Source Filing
The SEC filing that triggered this drug report: